Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
GOOGL, DPZ, PEP: Goldman Sachs Names Best Stocks to Buy Now
U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...
BioPharma Dive1h
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.
Merck releases positive phase 3 data on daily oral HIV drug
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
PipelineReview.com4h
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...
STAT4h
Lilly CEO got a big payday (and an Olympics treat)
Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...
STAT5h
Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...
BioSpace5h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
KFF Health News5h
Gilead’s HIV Drug Prevents Infection With One Shot A Year Instead Of Two
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...
News-Medical.Net6h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...